Ionis Pharmaceuticals has reopened enrollment in PrProfile, the first-in-human phase 1/2a trial of ION717, an antisense oligonucleotide given by lumbar puncture that is designed to lower production of prion protein. The updated ClinicalTrials.gov record (NCT06153966), revised on March 17, 2026, describes a trial now built from three regimens: regimens 1 and 2 are fully enrolled and were blinded, with participants receiving both ION717 and placebo in an undisclosed order during a 30-week treatment period, while regimen 3 is open label. In a letter to the prion disease community issued the same day, the company said regimen 3 will test an additional dosing regimen in approximately 20 more people with symptomatic prion disease, none of whom will receive placebo, and that the open-label extension has been lengthened from 70 weeks to 142 weeks. The estimated date for the primary study endpoint, which is a safety assessment, has moved to approximately February 2027.

PrProfile enrolled 56 symptomatic participants during 2024 and the last of them completed the blinded portion in July 2025, according to the trial's design history and contemporaneous community reporting. Ionis has released no numerical results. Its letter says the decision to expand was based on a review of interim data showing an "encouraging safety and tolerability profile" and evidence that ION717 is engaging prion protein, and states in the same document that those preliminary data are not sufficient to establish the drug's safety, tolerability or efficacy. The company says it intends to present data at medical and scientific conferences after the study reaches the revised primary completion date. The registry lists no posted results, and no peer-reviewed report of the trial has appeared.

For families, the practical facts are narrow. Regimen 3 is recruiting at a small number of already active sites, and the company says no new sites will be added and that not every existing site will take part. Eligibility is unchanged: adults with probable or definite prion disease, in the early stage at screening, with a caregiver, and able to travel for repeated intrathecal dosing. The full schedule set out in the registry is a screening period of up to six weeks, a 30-week treatment period, a 142-week open-label extension and a 32-week post-treatment period, which means participants joining now are committing to several years of visits.

The counterpoint is straightforward and the sponsor's own documents concede part of it. A single-arm, open-label group of about 20 people, followed for a long extension in a uniformly fatal disease, cannot on its own separate drug effect from the natural variation of prion disease, which differs widely by subtype and rate of progression. The reopening is neither a positive readout nor a futility stop: after 56 patients dosed across two blinded regimens, the sponsor has published nothing and has chosen to gather more. Prion protein lowering has a strong preclinical rationale in animal models, but that has never been shown to change the course of the disease in people, and it remains untested.